重组人促红细胞生成素在肿瘤相关性贫血中的临床应用

Clinical use of recombinant human erythropoietin in cancer related anemia

目的 探讨重组人促红细胞生成素（rhEPO）在治疗肿瘤相关性贫血中的临床疗效.方法 选择46例肿瘤相关性贫血患者,经皮下注射rhEPO 10 000 U每周3次治疗,无反应者增加至20000 U每周3次,4～6周为1个疗程.结果 28例患者经治疗后血红蛋白（Hb）明显上升,有效率为60.87％（28/46）.治疗前Hb为（67.45±2.05） g/L,治疗2周后为（71.05±1.73）g/L,治疗4周后为（78.45±2.20） g/L,治疗6周后为（90.65±3.42）g/L,差异有统计学意义（F=17.702,P＜ 0.05）.且随着治疗时间的延长,Hb水平逐渐升高,除治疗前与治疗2周后比较差异无统计学意义外,其余各时间点两两比较差异均有统计学意义（P＜0.05）.治疗后患者临床症状均有所好转,偶有头晕、乏力.治疗前KPS评分为40～70分,治疗后为60～90分,较治疗前显著提高.结论 应用rhEPO治疗肿瘤相关性贫血疗效明显,能有效提高Hb水平,改善患者生活质量.

Objective To explore the application of recombinant human erythropoietin（rhEPO） in the treatment of cancer related anemia.Methods Forty-six cases of patients with cancer related anemia were injected rhEPO 10 000 U subcutaneously three times a week.Non responders increased to 20 000 U three times a week,for 4 to 6 weeks.Results In 28 cases hemoglobin （Hb） increased significantly,and effective rate was 60.87％（28/46）.Hb was （67.45 ± 2.05） g/L before treatment,（71.05 ± 1.73） g/L after 2 weeks treatment,（78.45 ±2.20） g/L after 4 weeks treatment,and （90.65 ±3.42） g/L after 6 weeks treatment,the difference was statistically significant （F =17.702,P ＜ 0.05）.With the extension of treatment time,the Hb level increased.There was no statistically significant difference before treatment and 2 weeks after treatment,but the differences were statistically significant in other time point （P ＜0.05）.Clinical symptoms were improved after treatment with dizziness and fatique occasionally.KPS score were 40-70 scores before treatment,and 60-90 scores after treatment which was significantly higher than that before treatment.Conclusions The rhEPO in the treatment of cancer related anemia has obvious curative effect,and can effectively increase the Hb level and improve quality of life.